Novo Nordisk is facing a massive wave of generic competitors to its injectable formulations of GLP-1 agonist semaglutide, used to treat diabetes and obesity, as a key patent in India is due to expire ...

TORONTO - Anne Welch worked a physically demanding job at her local SPCA — lifting pets, cleaning kennels and walking dogs — until she retired at age 71. With the loss of that physical activity, ...

US slaps 100% tariffs on patented drugs Tariff exemption for generics shields most Indian drugmakers Sun Pharma faces capped 15% tariffs on innovative products. Did our AI summary help? Indian ...

Ozempic's and Wegovy's lowest doses of 0.25 mg in India will now be priced at 1,415 rupees ($15.04) for a weekly shot from 2,200 rupees and 2,712 rupees earlier, respectively, Novo Nordisk said in a ...

Danish pharmaceutical giant Novo Nordisk on Tuesday announced price cuts of up to 48% on its blockbuster diabetes and obesity drugs Ozempic and Wegovy in India, weeks after semaglutide—the active ...

Generic dapagliflozin is indicated for adults with type 2 diabetes and to reduce heart failure hospitalization risk in adults with T2D and established cardiovascular disease. The Food and Drug ...

March 31 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has again cut the prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 36% and 48% in India, to fend off ...

India is struggling with a rapid surge in type 2 diabetes and obesity. With the expiry of the patent for semaglutide, popularly known by the brand names Ozempic and WeGovy, and the entry of generic ...

Novo Nordisk (NVO) (NONOF) has once again reduced the prices of its GLP-1 medicine, semaglutide, in India as the company grapples with cheaper copycat versions of the popular GLP-1 therapy marketed as ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...